肝细胞癌和慢性乙型肝炎患者血清sFRP-1和β-catenin水平及临床意义*

doi:10.3969/j.issn.1672-5069.2014.01.019

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (1): 65-68.doi: 10.3969/j.issn.1672-5069.2014.01.019

肝细胞癌和慢性乙型肝炎患者血清sFRP-1和β-catenin水平及临床意义^*

李蕾, 薛如意, 沈锡中

200032 上海市复旦大学附属中山医院消化科

收稿日期:2013-09-10 出版日期:2014-02-28 发布日期:2016-04-11
通讯作者: 沈锡中,E-mail：shen.xizhong@zs-hospital.sh.cn
作者简介:李蕾,女,42岁,医学博士,主治医师。主要从事肝纤维化及消化系统肿瘤的防治研究。 E-mail：li.lei@zs-hospital.sh.cn
基金资助:
国家临床重点专科建设项目经费资助

Serum levels and clinical significance of sFRP-1 and β-catenin in patients with hepatocellular carcinoma and chronic hepatitis B

Li Lei, Xue Ruyi, Shen Xizhong

Department of Gastroenterology,Zhongshan Hospital,Fudan University,Shanghai 200032,China

Received:2013-09-10 Online:2014-02-28 Published:2016-04-11

摘要/Abstract

摘要： 目的探讨肝细胞癌（hepatocellular carcinoma, HCC）和慢性乙型肝炎（chronic hepatitis B,CHB）患者血清分泌型卷曲相关蛋白-1（secreted frizzled-related proteins, sFRP-1）和β-catenin水平及临床意义。方法采用ELISA法检测36例HCC、36例CHB和36例正常人血清sFRP-1和β-catenin水平,应用Spearman相关分析,分析血清sFRP-1和β-catenin水平与年龄、丙氨酸氨基转移酶（ALT）、白蛋白和总胆红素等的相关性。结果HCC和CHB患者血清sFRP-1水平分别为（1136.28±332.43）pg/ml和（1194.53±156.84）pg/ml,均显著低于正常人[（1477.26±563.12）pg/ml,P<0.05];HCC患者血清β-catenin水平为（527.2±20.9）pg/ml,显著高于正常人和CHB患者[分别为（369.8±21.5）pg/ml和（374.0±8.3）pg/ml,P<0.05];HCC和CHB患者血清sFRP-1和β-catenin水平与年龄、ALT、白蛋白、总胆红素无显著相关性。结论肝细胞癌和慢性乙型肝炎患者血清sFRP-1降低,而肝细胞癌患者血清β-catenin水平升高。

关键词: 肝细胞癌, 慢性乙型肝炎, 分泌型卷曲相关蛋白-1, β, -catenin

Abstract: Objective To evaluate serum levels and clinical significance of secreted frizzled-related proteins （sFRP）-1 and β-catenin in patients with hepatocellular carcinoma（HCC）and chronic hepatitis B （CHB）. MethodsSerum levels of sFRP-1 and β-catenin in 36 patients with HCC,36 patients with CHB and 36 healthy persons were detected by ELISA;Spearman correlation analysis was used to estimate the relevance between sFRP-1, β-catenin and age,ALT,albumin,total bilirubin. Results The serum levels of sFRP-1 in patients with HCC and CHB were（1136.28±332.43） pg/ml and（1194.53±156.84） pg/ml,respectively,both significantly higher than that in healthy persons[（1477.26±563.12） pg/ml,P<0.05];The serum level of β-catenin in patients with HCC was （527.2±20.9） pg/ml,significantly higher than those in patients with CHB（374.0±8.3） pg/ml and normal persons （369.8±21.5） pg/ml,P<0.05）;No correlation was found between serum sFRP-1 or β-catenin levels with age,ALT,albumin,total bilirubin either in CHB or in HCC group. Conclusion The serum sFRP-1 levels in patients with HCC and CHB decrease,while the serum β-catenin levels in patients with HCC increase.

Key words: Hepatocellular carcinoma, Hepatitis B, Secreted frizzled-related proteins -1, β, -catenin

李蕾, 薛如意, 沈锡中. 肝细胞癌和慢性乙型肝炎患者血清sFRP-1和β-catenin水平及临床意义^*[J]. 实用肝脏病杂志, 2014, 17(1): 65-68.

Li Lei, Xue Ruyi, Shen Xizhong. Serum levels and clinical significance of sFRP-1 and β-catenin in patients with hepatocellular carcinoma and chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 65-68.

参考文献

[1] Surendran K,Mccaul SP,Simon TC. A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physical,2002,282（3）：431-441.
[2] Myung SJ,Yoon JH,Gwak GY,et al. Wnt signaling enhances the activation and survival of human hepatic stellate cells. FEBS Lett,2007,581：2954-2958.
[3] Jiang F,Parsons CJ,Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol,2006,45：401-409.
[4] Ban KC,Singh H,Krishnan R,et al. GSK-3β phosphorylation and alteration of β-catenin in hepatocellular carcinoma. Cancer Lett,2003,199：201-208.
[5] Taylor MD,Rutka JT. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene,2010,29：3017-3024.
[6] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志,2011,14（2）：81-89.
[7] Muroyama Y,Fujihara M,Ikeya M,et al. Wnt signaling plays an essential role in neuronal specification of the dorsal spinal cord. Genes Dev,2002,16：548-553.
[8] Peterson CP,Reddien PW. Wnt signaling and the polarity of the primary body axis. Cell,2009,139：1056-1068.
[9] Gregory MA,Phang TL,Neviani P,et al. Wnt/Ca2 + /NFAT signaling maintains survival of Ph + leukemia cells upon inhibition of Bcr-Abl. Cancer Cell,2010,18： 74-87.
[10] Vijayakumar S,Liu G,Rus IA,et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene,CDC25A. Cancer Cell,2011,19：601-612.
[11] Thompson MD,Monga SP. WNT/β-catenin signaling in liver health and disease. Hepatology,2007,45（5）：1298-305.
[12] Kongkham PN,Northcott PA,Croul SE,et al. The SFRP family of WNT inhibitors function as novel tumor suppressor genes epigenetically silenced in medulloblastoma. Oncogene,2010,29：3017-3024.
[13] Shih YL,Hsieh CB,Lai HC,et al. SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway. Int J Cancer,2007,121（5）：1028-1035.
[14] Lopez-Knowles E,Zardawi SJ. Cytoplasmic localization of β-catenin is a marker of poor outcome in breast cancer patients. Cancer Epi Bio Pre,2010,19（1）：301-309.
[15] Sangkhathat S,Kusafuka T,Miao JY,et al. In vitro RNA interference against β-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol,2006,28（3）：715-722.
[16] 葛文松,吴建新,范建高,等. siRNA 沉默β-Catenin 对肝星状细胞增殖和凋亡的影响. 实用肝脏病杂志,2011,14（2）：91-94.

肝细胞癌和慢性乙型肝炎患者血清sFRP-1和β-catenin水平及临床意义^*

Serum levels and clinical significance of sFRP-1 and β-catenin in patients with hepatocellular carcinoma and chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[2]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[3]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[4]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[5]	曹策, 郁义星, 王贝贝, 赵卫峰. 增强磁共振成像联合血清甲胎蛋白和脱-γ-羧基凝血酶原诊断肝细胞癌临床价值探讨[J]. 实用肝脏病杂志, 2019, 22(6): 896-899.
[6]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[7]	赵协山, 伍春瑢, 王春峰, 余积洁, 何青. 替诺福韦联合安络化纤丸治疗HBeAg阴性慢性乙型肝炎患者疗效及其血清肝纤维化指标的变化研究*[J]. 实用肝脏病杂志, 2019, 22(5): 644-647.
[8]	涂杰霞, 王安娜, 廖若汐. 干扰素α-2b与聚乙二醇干扰素α-2a治疗慢性乙型肝炎患者疗效比较研究*[J]. 实用肝脏病杂志, 2019, 22(5): 648-651.
[9]	高伟, 侯勇. 肝脏硬度值检测诊断慢性乙型肝炎患者肝组织纤维化的效能分析*[J]. 实用肝脏病杂志, 2019, 22(5): 652-655.
[10]	朱俊, 丁莹, 王世清, 张野, 刘野, 刘泽刚. 围手术期应用乌司他丁治疗对肝细胞癌患者肝切除术后外周血Th22细胞百分比和血浆白细胞介素-22的影响*[J]. 实用肝脏病杂志, 2019, 22(5): 720-723.
[11]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[12]	白一春, 邓霁红, 梅小平. 影响聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者疗效的多因素分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 490-493.
[13]	程华, 鞠辉, 宋德顺, 李伟. 慢性乙型肝炎患者血清血管生成素样蛋白2和高尔基体蛋白73水平变化及其诊断显著肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 494-497.
[14]	李高明, 吕必华. 菖郁逍遥散治疗慢性乙型肝炎伴抑郁患者负性情绪和中医证候积分的变化^*[J]. 实用肝脏病杂志, 2019, 22(4): 498-501.
[15]	余英芳, 温生宝. 应用磁共振DWI单指数、双指数和拉伸指数模型参数评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 502-505.